| Noncatalytic antioxidant role for Helicobacter pylori urease AA Schmalstig, SL Benoit, SK Misra, JS Sharp, RJ Maier Journal of bacteriology 200 (17), 10.1128/jb. 00124-18, 2018 | 35 | 2018 |
| Nickel chelation therapy as an approach to combat multi-drug resistant enteric pathogens SL Benoit, AA Schmalstig, J Glushka, SE Maier, AS Edison, RJ Maier Scientific Reports 9 (1), 13851, 2019 | 16 | 2019 |
| A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis M Kim, CE Johnson, AA Schmalstig, A Annis, SE Wessel, B Van Horn, ... Nature communications 13 (1), 4455, 2022 | 10 | 2022 |
| Reapproaching old treatments: Considerations for PK/PD studies on phage therapy for bacterial respiratory infections AA Schmalstig, S Freidy, PO Hanafin, M Braunstein, GG Rao Clinical Pharmacology & Therapeutics 109 (6), 1443-1456, 2021 | 10 | 2021 |
| Thiopeptides induce proteasome-independent activation of cellular mitophagy KE Bird, C Xander, S Murcia, AA Schmalstig, X Wang, MJ Emanuele, ... ACS chemical biology 15 (8), 2164-2174, 2020 | 10 | 2020 |
| Mycobacterium abscessus drug discovery using machine learning AA Schmalstig, KM Zorn, S Murcia, A Robinson, S Savina, E Komarova, ... Tuberculosis 132, 102168, 2022 | 6 | 2022 |
| Bacteriophage infection and killing of intracellular Mycobacterium abscessus AA Schmalstig, A Wiggins, D Badillo, KS Wetzel, GF Hatfull, M Braunstein Mbio 15 (1), e02924-23, 2024 | 1 | 2024 |
| Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations SB Yeshwante, P Hanafin, BK Miller, L Rank, S Murcia, C Xander, A Annis, ... Molecular Pharmaceutics 20 (9), 4491-4504, 2023 | | 2023 |
